Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of
neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and
Pertuzumab given as neoadjuvant treatment in HER2 positive early-stage or locally advanced
breast cancer.